FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248045393> ?p ?o ?g. }

• W4248045393 endingPage "606" @default.
• W4248045393 startingPage "606" @default.
• W4248045393 abstract "606 Background: Pertuzumab is a monoclonal antibody which binds to extracellular domain II of HER2 distally from trastuzumab, disrupting HER2 dimerization and signaling. Pertuzumab improves progression-free survival (PFS) and overall survival when combined with docetaxel/trastuzumab. We report results of a phase II study to evaluate the efficacy and safety of pertuzumab, trastuzumab and weekly paclitaxel. Methods: Patients (pts) with HER2+ MBC with 0-1 prior treatment (Rx) were eligible. Rx is weekly (w) paclitaxel (80mg/m 2 ), q3w trastuzumab (loading dose 8mg/kg → 6mg/kg), and q3w pertuzumab (flat loading dose 840mg → 420mg). The primary endpoint is PFS at 6 months (mo). Evaluable pts are those who started study Rx and are assessed at 6 mo for PFS, including pts who progressed prior to 6mo. Secondary endpoints include response, safety (including cardiac events), and tolerability. Left ventricular ejection fraction (LVEF) is monitored by echocardiogram every 3 mo. Cardiac events are defined as symptomatic LV systolic dysfunction (LVSD), non-LVSD cardiac death, or probable cardiac death. Results: As of 1-18-13, 53 pts are enrolled; 36 are evaluable at 6 mo. At 6 mo, 29/36 pts (81%) are progression-free (4 CR, 14 PR and 11 SD); 7 pts progressed. The 6 mo PFS results for all patients will be updated. Median LVEF is 64% at baseline (range 50-72%), 63% at 3 mo (range 50-73%), and 62% at 6 mo (range 49-69%). There are no cardiac events to date. Of the 36 pts, grade 3/4 toxicities include fatigue (3 pts, 8%), peripheral neuropathy (2 pts, 6%), sepsis (1pt, 3%), cellulitis (1pt, 3%), neutropenia (1pt, 3%), and skin ulceration (1pt, 3%). There are no grade 3 diarrhea or febrile neutropenic events in the evaluable pts to date. Conclusions: The preliminary 6-month PFS is 81% (95% CI 67-91%) in evaluable patients. The study is closing to accrual. Treatment is ongoing, with few grade 3/4 toxicities and no signal of increased cardiac toxicity to date. This phase II study demonstrates efficacy and safety for pertuzumab with trastuzumab and weekly paclitaxel in HER2+ MBC. Clinical trial information: NCT01276041." @default.
• W4248045393 created "2022-05-12" @default.
• W4248045393 creator A5009038938 @default.
• W4248045393 creator A5009811727 @default.
• W4248045393 creator A5011528560 @default.
• W4248045393 creator A5011803946 @default.
• W4248045393 creator A5014773662 @default.
• W4248045393 creator A5016728798 @default.
• W4248045393 creator A5019041034 @default.
• W4248045393 creator A5019910948 @default.
• W4248045393 creator A5034917686 @default.
• W4248045393 creator A5041961484 @default.
• W4248045393 creator A5042880438 @default.
• W4248045393 creator A5047713528 @default.
• W4248045393 creator A5052906334 @default.
• W4248045393 creator A5056983888 @default.
• W4248045393 creator A5068207600 @default.
• W4248045393 creator A5069656105 @default.
• W4248045393 creator A5069795948 @default.
• W4248045393 creator A5076749646 @default.
• W4248045393 creator A5087460036 @default.
• W4248045393 date "2013-05-20" @default.
• W4248045393 modified "2023-09-27" @default.
• W4248045393 title "Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)." @default.
• W4248045393 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.606" @default.
• W4248045393 hasPublicationYear "2013" @default.
• W4248045393 type Work @default.
• W4248045393 citedByCount "5" @default.
• W4248045393 countsByYear W42480453932014 @default.
• W4248045393 countsByYear W42480453932015 @default.
• W4248045393 countsByYear W42480453932022 @default.
• W4248045393 crossrefType "journal-article" @default.
• W4248045393 hasAuthorship W4248045393A5009038938 @default.
• W4248045393 hasAuthorship W4248045393A5009811727 @default.
• W4248045393 hasAuthorship W4248045393A5011528560 @default.
• W4248045393 hasAuthorship W4248045393A5011803946 @default.
• W4248045393 hasAuthorship W4248045393A5014773662 @default.
• W4248045393 hasAuthorship W4248045393A5016728798 @default.
• W4248045393 hasAuthorship W4248045393A5019041034 @default.
• W4248045393 hasAuthorship W4248045393A5019910948 @default.
• W4248045393 hasAuthorship W4248045393A5034917686 @default.
• W4248045393 hasAuthorship W4248045393A5041961484 @default.
• W4248045393 hasAuthorship W4248045393A5042880438 @default.
• W4248045393 hasAuthorship W4248045393A5047713528 @default.
• W4248045393 hasAuthorship W4248045393A5052906334 @default.
• W4248045393 hasAuthorship W4248045393A5056983888 @default.
• W4248045393 hasAuthorship W4248045393A5068207600 @default.
• W4248045393 hasAuthorship W4248045393A5069656105 @default.
• W4248045393 hasAuthorship W4248045393A5069795948 @default.
• W4248045393 hasAuthorship W4248045393A5076749646 @default.
• W4248045393 hasAuthorship W4248045393A5087460036 @default.
• W4248045393 hasConcept C121608353 @default.
• W4248045393 hasConcept C126322002 @default.
• W4248045393 hasConcept C143998085 @default.
• W4248045393 hasConcept C197934379 @default.
• W4248045393 hasConcept C203092338 @default.
• W4248045393 hasConcept C2775930923 @default.
• W4248045393 hasConcept C2777292972 @default.
• W4248045393 hasConcept C2778198053 @default.
• W4248045393 hasConcept C2778375690 @default.
• W4248045393 hasConcept C2779786085 @default.
• W4248045393 hasConcept C2781164504 @default.
• W4248045393 hasConcept C2781190966 @default.
• W4248045393 hasConcept C530470458 @default.
• W4248045393 hasConcept C535046627 @default.
• W4248045393 hasConcept C71924100 @default.
• W4248045393 hasConcept C78085059 @default.
• W4248045393 hasConceptScore W4248045393C121608353 @default.
• W4248045393 hasConceptScore W4248045393C126322002 @default.
• W4248045393 hasConceptScore W4248045393C143998085 @default.
• W4248045393 hasConceptScore W4248045393C197934379 @default.
• W4248045393 hasConceptScore W4248045393C203092338 @default.
• W4248045393 hasConceptScore W4248045393C2775930923 @default.
• W4248045393 hasConceptScore W4248045393C2777292972 @default.
• W4248045393 hasConceptScore W4248045393C2778198053 @default.
• W4248045393 hasConceptScore W4248045393C2778375690 @default.
• W4248045393 hasConceptScore W4248045393C2779786085 @default.
• W4248045393 hasConceptScore W4248045393C2781164504 @default.
• W4248045393 hasConceptScore W4248045393C2781190966 @default.
• W4248045393 hasConceptScore W4248045393C530470458 @default.
• W4248045393 hasConceptScore W4248045393C535046627 @default.
• W4248045393 hasConceptScore W4248045393C71924100 @default.
• W4248045393 hasConceptScore W4248045393C78085059 @default.
• W4248045393 hasIssue "15_suppl" @default.
• W4248045393 hasLocation W42480453931 @default.
• W4248045393 hasOpenAccess W4248045393 @default.
• W4248045393 hasPrimaryLocation W42480453931 @default.
• W4248045393 hasRelatedWork W13154270 @default.
• W4248045393 hasRelatedWork W16909223 @default.
• W4248045393 hasRelatedWork W22239221 @default.
• W4248045393 hasRelatedWork W2337926 @default.
• W4248045393 hasRelatedWork W25071997 @default.
• W4248045393 hasRelatedWork W25774907 @default.
• W4248045393 hasRelatedWork W25836112 @default.
• W4248045393 hasRelatedWork W3984105 @default.
• W4248045393 hasRelatedWork W4741852 @default.
• W4248045393 hasRelatedWork W5387012 @default.
• W4248045393 hasVolume "31" @default.

• next